利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.031 秒)

    METHOD FOR MEASUREMENT OF HEMOGLOBIN AND HEMOGLOBIN DERIVATIVE, AND MEASUREMENT KIT
    3.
    发明申请
    METHOD FOR MEASUREMENT OF HEMOGLOBIN AND HEMOGLOBIN DERIVATIVE, AND MEASUREMENT KIT 有权
    测量HEMOGLOBIN和HEMOGLOBIN衍生物的方法和测量试剂盒

    公开(公告)号：US20100267048A1

    公开(公告)日：2010-10-21

    申请号：US12740857

    申请日：2008-10-29

    申请人： Hirotaka Tanaka ,  Masanori Tanaka ,  Chizu Asahara ,  Fumihisa Kitawaki

    发明人： Hirotaka Tanaka ,  Masanori Tanaka ,  Chizu Asahara ,  Fumihisa Kitawaki

    IPC分类号： G01N33/53 ,  C12M1/34

    CPC分类号： G01N33/721 ,  G01N33/541 ,  G01N33/543 ,  G01N33/723 ,  G01N33/726 ,  Y10T436/105831 ,  Y10T436/25125 ,  Y10T436/2525 ,  Y10T436/25375

    摘要： Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative.

    摘要翻译： 样品溶液中的血红蛋白迅速可靠地变性; 同时，实现血红蛋白和血红蛋白衍生物的快速准确测定。 在本方法中使用的血红蛋白和血红蛋白衍生物，试剂组合物，测定试剂盒，分析装置和分析系统的测定方法中，将含有血液成分的试样溶液用非离子性表面活性剂，氧化剂 和金属盐，使样品溶液中的血红蛋白变性，测定血红蛋白，然后用特异性结合变性血红蛋白衍生物的变性部位的抗体的免疫学方法测定样品中的血红蛋白衍生物的量。

    Liquid homogenizer and analyzer employing the same
    4.
    发明授权
    Liquid homogenizer and analyzer employing the same 有权
    液体均化器和采用其的分析仪

    公开(公告)号：US07754151B2

    公开(公告)日：2010-07-13

    申请号：US11910513

    申请日：2006-03-24

    申请人： Fumihisa Kitawaki ,  Hirotaka Tanaka ,  Kenji Watanabe

    发明人： Fumihisa Kitawaki ,  Hirotaka Tanaka ,  Kenji Watanabe

    IPC分类号： G01N9/30

    CPC分类号： B01F3/08 ,  B01F13/0059 ,  B01F15/0233 ,  B01F2215/0037 ,  G01N21/07 ,  G01N35/00069 ,  G01N2035/00495 ,  G01N2035/00524 ,  Y10T436/111666 ,  Y10T436/2575

    摘要： Herein disclosed is a liquid homogenizer for mixing two or more liquids, comprising: a rotator (1) rotatable around a rotation axis; at least two liquid-mixing chambers (6, 10) formed in the rotator, and being different from each other in distance from the rotation axis; and at least two channels (8) through which one of the liquid-mixing chambers is communicated with the other of the liquid-mixing chambers (6, 10), wherein the liquid-mixing chambers (6, 10) include an outer liquid-mixing chamber (10) and an inner liquid-mixing chamber (6) close to the rotation axis in comparison with the outer liquid-mixing chamber, when the rotator (1) is rotating around the rotation axis, the liquids are shifted by a centrifugal force to the outer liquid-mixing chamber from the inner liquid-mixing chamber through the channels (8), and agitated to be mixed by turbulent flows in the outer liquid-mixing chamber.

    摘要翻译： 本文公开了一种用于混合两种或更多种液体的液体均化器，包括：可围绕旋转轴线旋转的旋转体（1） 形成在旋转体中的至少两个液体混合室（6,10），并且与旋转轴线的距离彼此不同; 和至少两个通道（8），其中一个液体混合室通过该通道与另一个液体混合室（6,10）连通，其中液体混合室（6,10）包括外部液体 - 混合室（10）和与外部液体混合室相比靠近旋转轴线的内部混合室（6），当旋转体（1）围绕旋转轴线旋转时，液体被离心 通过通道（8）从内部液体混合室向外部液体混合室施力，并搅拌以在外部混合室中被湍流混合。

    Biosensor
    5.
    发明授权
    Biosensor 有权
    生物传感器

    公开(公告)号：US07575915B2

    公开(公告)日：2009-08-18

    申请号：US10031988

    申请日：2001-05-25

    申请人： Masataka Nadaoka ,  Mie Takahashi ,  Hirotaka Tanaka ,  Fumihisa Kitawaki

    发明人： Masataka Nadaoka ,  Mie Takahashi ,  Hirotaka Tanaka ,  Fumihisa Kitawaki

    IPC分类号： G01N33/558

    CPC分类号： G01N33/558 ,  Y10S435/81 ,  Y10S435/97 ,  Y10S436/805 ,  Y10S436/807

    摘要： A biosensor is provided with a development layer for developing an inspection target solution, that has a reagent immobilization part where an antibody for a measurement target in the inspection target solution is immobilized and a reagent holding part which marks in a dry state and holds an antibody which can be eluted by development of the inspection target solution in parts of the development layer. The biosensor measures a bonding amount of the marker reagent bonded to the reagent immobilization part, thereby qualitatively or quantitatively measuring components to be measured in the inspection target solution, and is further provided with a space forming material that forms a cavity part, which is a space into which the inspection target solution flows, between the development layer for developing the inspection target solution and the space forming material.

    摘要翻译： 生物传感器设置有用于开发检查对象溶液的显影层，其具有固定有检查对象溶液中的测定对象的抗体的试剂固定部以及标记为干燥状态并保持抗体的试剂保持部 其可以通过在显影层的部分中开发检查目标溶液而被洗脱。 生物传感器测定与试剂固定部接合的标记试剂的结合量，从而定量或定量地测量检查对象溶液中待测量的成分，并且还设置有空间形成材料，其形成空腔部分，其为 检查对象溶液流动的空间，用于显影检查对象溶液的显影层和空间形成材料之间。

    SN-ZN LEAD-FREE SOLDER ALLOY, AND SOLDER JUNCTION PORTION
    7.
    发明申请
    SN-ZN LEAD-FREE SOLDER ALLOY, AND SOLDER JUNCTION PORTION 失效
    SN-ZN无铅焊接合金和焊接接头部分

    公开(公告)号：US20060204397A1

    公开(公告)日：2006-09-14

    申请号：US11433325

    申请日：2006-05-12

    申请人： Masaaki Yoshikawa ,  Haruo Aoyama ,  Hirotaka Tanaka

    发明人： Masaaki Yoshikawa ,  Haruo Aoyama ,  Hirotaka Tanaka

    IPC分类号： C22C13/02

    CPC分类号： C22C13/00 ,  B23K35/0244 ,  B23K35/262 ,  B23K35/36 ,  B23K2101/42

    摘要： An Sn—Zn lead-free solder alloy according to the present invention is constructed in a manner such that it is an Sn-based solder alloy indispensably containing 6 to 10 wt % zinc at least and further containing 0.0015 to 0.03 wt % magnesium and 0.0010 to 0.006 wt % aluminum. Upon preservation of solder paste not only under refrigeration but also at a room temperature or higher, the inside of solder particle is protected by the protective magnesium/aluminum oxide film formed on the solder particle surface, and a reaction between zinc and an activator is suppressed, so that preservation stability is improved, and at the elevated temperature during soldering, the solder alloy enters a state where said protective oxide film is easily destroyed, so that good wettability is held.

    摘要翻译： 根据本发明的Sn-Zn无铅焊料合金是以至少含有至少还含有0.0015-0.03％（重量）镁和0.0010（重量％）的6至10％重量的锌的Sn基焊料合金构成的 至0.006重量％的铝。 在不仅在制冷下还能在室温以上保存焊膏的情况下，通过在焊料粒子表面形成的保护性镁/氧化铝膜来保护焊锡颗粒的内部，抑制锌与活化剂的反应 ，从而保持稳定性提高，并且在焊接时的高温下，焊料合金进入容易破坏所述保护氧化膜的状态，从而保持良好的润湿性。

    Magnetic recording medium
    8.
    发明授权
    Magnetic recording medium 有权
    磁记录介质

    公开(公告)号：US07081308B2

    公开(公告)日：2006-07-25

    申请号：US10858198

    申请日：2004-06-02

    申请人： Hisao Kawai ,  Teiichiro Umezawa ,  Hirotaka Tanaka ,  Masaki Uemura

    发明人： Hisao Kawai ,  Teiichiro Umezawa ,  Hirotaka Tanaka ,  Masaki Uemura

    IPC分类号： G11B5/66 ,  G11B5/70

    CPC分类号： G11B5/66

    摘要： In a magnetic recording medium including a substrate (1) having a principal surface on which first and second magnetic layers (5 and 7) and a spacer layer (6) are at least formed, each of the first and the second magnetic layers being of a ferromagnetic material, the spacer layer being formed between the first and the second magnetic layers for inducing antiferromagnetic exchange interaction between the first and the second magnetic layers, the principal surface of the substrate is provided with concentric textures to have a predetermined surface roughness so that the spacer layer has a uniform thickness. The first magnetic layer is for controlling the antiferromagnetic exchange interaction.

    摘要翻译： 在包括具有至少形成第一和第二磁性层（5和7）和间隔层（6）的主表面的基底（1）的磁记录介质中，第一和第二磁性层中的每一个是 所述间隔层形成在所述第一和第二磁性层之间，用于在所述第一和第二磁性层之间引起反铁磁交换相互作用，所述基板的主表面设置有同心纹理以具有预定的表面粗糙度，使得 间隔层具有均匀的厚度。 第一磁性层用于控制反铁磁交换相互作用。

    Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
    9.
    发明授权
    Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists 失效

    公开(公告)号：US07915448B2

    公开(公告)日：2011-03-29

    申请号：US12578061

    申请日：2009-10-13

    申请人： Takeshi Hanazawa ,  Misato Hirano ,  Tadashi Inoue ,  Satoshi Nagayama ,  Kazunari Nakao ,  Yuji Shishido ,  Hirotaka Tanaka

    发明人： Takeshi Hanazawa ,  Misato Hirano ,  Tadashi Inoue ,  Satoshi Nagayama ,  Kazunari Nakao ,  Yuji Shishido ,  Hirotaka Tanaka

    IPC分类号： C07C311/03 ,  A61K31/18

    CPC分类号： C07C61/28 ,  C07C61/40 ,  C07C311/08 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07D213/26 ,  C07D213/56 ,  C07D213/74 ,  C07D213/76

    摘要： This invention provides a compound of the formula (I): wherein A and B are independently CR12 or N; D and E are each independently CR9 or N; R1 represents (C1-C6)alkyl; R2 represents hydrogen, halogen, hydroxy, (C1-C6) alkyl, halo(C1-C6) alkyl, hydroxy(C1-C6) alkyl, (C1-C6)alkoxy or (C1-C6)alkoxy-(C1-C6)alkyl; R3, R4, R5, R6, R10 and R11 each independently represent hydrogen, halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl or (C1-C6)alkoxy-(C1-C6)alkyl; or R3 and R4 are taken together with the carbon atom to which they are attached to form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which one or two non-adjacent carbon atoms are optionally replaced by an oxygen atom, a sulfur atom or NH; R7 and R9 each independently represent hydrogen, halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, NH2, [(C1-C6)alkyl]NH—, [(C1-C6)alkyl]2N—, H2N—(C1-C6)alkoxy, (C1-C6)alkyl-NH—(C1-C6)alkoxy, [(C1-C6)alkyl]2N(C1-C6)alkoxy; H2N—(C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkyl-NH—(C1-C6)alkoxy-(C1-C6)alkyl, [(C1-C6)alkyl]2N(C1-C6)alkoxy-(C1-C6)alkyl or 5- or 6- membered heterocyclic ring containing at least one nitrogen atom; R8 represents halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, halo(C1-C6)alkylsulfonyl, halo(C1-C6)alkylsulfinyl, halo(C1-C6)alkoxy, halo(C1-C6)alkylthio, [(C1-C6)alkyl]NH— or [(C1-C6)alkyl]2N—; or R7 and R8, when E is CR9, are taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, in which one or two non-adjacent carbon atoms are optionally replaced by oxygen, sulfur, N or NH groups, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents each independently selected from the group consisting of hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy and hydroxy(C1-C6)alkyl; and R12 represents hydrogen, halogen, (C1-C6)alkyl or hydroxy(C1-C6)alkyl; or a pharmaceutically acceptable salt or solvate thereof.